Adjuvant Chemotherapy and Survival After Pelvic Exenteration for Gynecologic Cancers in the COREPEX Study - Report - MDSpire

Adjuvant Chemotherapy and Survival After Pelvic Exenteration for Gynecologic Cancers in the COREPEX Study

  • By

  • Nicolò Bizzarri

  • Zoltan Novák

  • Giulio Ricotta

  • Mihai Emil Cãpîlna

  • Diana Giannarelli

  • Santiago Domingo

  • Vito Chiantera

  • Hüseyin Akıllı

  • David Cibula

  • Diana Zach

  • Andrea Miranda

  • Porfyrios Korompelis

  • Enrique Chacon

  • Ignacio Zapardiel

  • Björn Lampe

  • Valentyn Svintsitskyi

  • Olga Matylevich

  • Gabrielle H. van Ramshorst

  • Cagatay Taskiran

  • Fuat Demirkıran

  • Tibor Lengyel

  • Giuseppe Vizzielli

  • Matteo Loverro

  • Francesco Fanfani

  • Claudia Marchetti

  • Gwenael Ferron

  • Alejandra Martinez

  • Elodie Gauroy

  • Emmanuel Ladanyi

  • Leo Szilard Kiss

  • Victor Lago

  • Manel Montesinos-Albert

  • Mariano Catello Di Donna

  • Giuseppe Cucinella

  • Jiri Slama

  • Viktória Rosta

  • Mustafa Zelal Muallem

  • Ali Kucukmetin

  • Anna Fagotti

  • Sahar Salehi

  • Denis Querleu

  • June 26, 2026

  • 0 min

Share

Clinical Report: Impact of Adjuvant Chemotherapy on Survival Outcomes Following Pelvic Exenteration for Gynecologic Malignancies

Overview

The COREPEX study analyzed the impact of adjuvant chemotherapy on survival outcomes in patients undergoing pelvic exenteration for gynecologic malignancies. Results indicated that adjuvant chemotherapy was associated with improved overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS) in this patient population.

Background

Pelvic exenteration is a radical surgical procedure for gynecologic cancers, often performed in cases with pelvic lymph node metastasis. Understanding the role of adjuvant chemotherapy in improving survival outcomes is crucial, as previous studies have shown mixed results regarding its efficacy. This study aims to clarify the association between adjuvant chemotherapy and survival metrics in patients undergoing this procedure.

Data Highlights

ParameterAdjuvant ChemotherapyNo Adjuvant ChemotherapyP-value
Median DFS (months)20 (95% CI, 10.7-29.3)7 (95% CI, 3.5-10.5)0.001
Median OS (months)28 (95% CI, 22.4-33.5)10 (95% CI, 6.6-13.4)<0.001
Median CSS (months)28 (95% CI, 22.6-33.4)13 (95% CI, 8.0-18.0)0.001

Key Findings

  • Adjuvant chemotherapy was associated with improved median DFS (20 months vs 7 months; P = 0.001).
  • Patients receiving adjuvant chemotherapy had a median OS of 28 months compared to 10 months for those who did not (P < 0.001).
  • Cancer-specific survival was also significantly better in the chemotherapy group (28 months vs 13 months; P = 0.001).
  • Multivariable analysis indicated adjuvant chemotherapy as the only independent factor associated with improved DFS and OS.
  • No significant difference in para-aortic or distant recurrences was observed between the two groups (P = 0.94).

Clinical Implications

The findings indicate that adjuvant chemotherapy was associated with improved survival metrics in patients undergoing pelvic exenteration for gynecologic malignancies.

Conclusion

Adjuvant chemotherapy was associated with improved survival outcomes in patients undergoing pelvic exenteration for gynecologic cancers.

Related Resources & Content

  1. COREPEX Study, Complications and Recurrence After Pelvic Exenteration, 2025 -- Impact of Adjuvant Chemotherapy on Survival Outcomes
  2. The ASCO Post — Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes
  3. the asco post — Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes
  4. The ASCO Post — Adjuvant Chemoradiotherapy vs Radiotherapy Alone in High-Risk Endometrial Cancer
  5. The ASCO Post — Expert Point of View: Kunle Odunsi, MD, PhD and Lilian T. Gien, MD, MSc
  6. NCCN Guidelines Insights: Cervical Cancer, Version 1.2024
  7. ESGO-ESTRO-ESP Guidelines for Endometrial Carcinoma
  8. Treatment of Pelvic Recurrence After Radiotherapy for Cervical Cancer - PMC
  9. Evaluation of survival and mortality in pelvic exenteration for gynecologic malignancies: a systematic review, meta-analyses, and meta-regression study - ScienceDirect
  10. Complications and Recurrence After Pelvic Exenteration for Gynecologic Malignancies: Survival Analysis From the COREPEX Study - PMC
  11. Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies - PubMed

Original Source(s)

Adjuvant Chemotherapy and Survival After Pelvic Exenteration for Gynecologic Cancers in the COREPEX Study

  • by Nicolò Bizzarri, Zoltan Novák, Giulio Ricotta, Mihai Emil Cãpîlna, Diana Giannarelli, Santiago Domingo, Vito Chiantera, Hüseyin Akıllı, David Cibula, Diana Zach, Andrea Miranda, Porfyrios Korompelis, Enrique Chacon, Ignacio Zapardiel, Björn Lampe, Valentyn Svintsitskyi, Olga Matylevich, Gabrielle H. van Ramshorst, Cagatay Taskiran, Fuat Demirkıran, Tibor Lengyel, Giuseppe Vizzielli, Matteo Loverro, Francesco Fanfani, Claudia Marchetti, Gwenael Ferron, Alejandra Martinez, Elodie Gauroy, Emmanuel Ladanyi, Leo Szilard Kiss, Victor Lago, Manel Montesinos-Albert, Mariano Catello Di Donna, Giuseppe Cucinella, Jiri Slama, Viktória Rosta, Mustafa Zelal Muallem, Ali Kucukmetin, Anna Fagotti, Sahar Salehi, Denis Querleu

  • June 26, 2026

Related Content

Navigating specific targets of psychoneurological symptom cluster in breast cancer: a computer-simulated network analysis

Biopharma Vital Signs – Part 2: Emerging Trends

Industry experts discuss the trends reshaping biotech and biopharma development – from complex modalities and manufacturing pressures to AI, funding constraints, and the growing need to plan for commercialization earlier

  • June 26, 2026

  • 10 min
Effectiveness of a Home-Based and Group-Based Tele-Exercise Program for Breast Cancer Survivors: Pilot Randomized Controlled Trial